Project Grant R21AI192340
Award Date 9/2/26
Completion Date 8/31/28
Dollars Obligated $224K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Greenville, NC 27858, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded East Carolina University $226,500 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research characterizing how zinc depletion and host calprotectin balance impact pulmonary inflammation during pneumonic plague infection. The research investigates the role of Yersinia pestis YbtX, an inner membrane protein and zinc transporter, in driving the hyper-inflammatory response that...
- The National Institute of Allergy and Infectious Diseases awarded the University of Louisville $630,173 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how Yersinia pestis modulates host extracellular vesicles and evades immune response in pneumonic plague. The research defines changes in pulmonary extracellular vesicle populations and inflammatory potential during pneumonic plague infection, and uses Y. pestis mutants to delineate the...
- The National Institute of Allergy and Infectious Diseases awarded the University of Louisville $152,600 on October 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the impact of prostaglandins on Yersinia pestis infection. The research addresses how prostaglandins—host-derived lipid mediators—modulate the immune response during plague infection. Yersinia pestis uses a type 3 secretion system to suppress the host inflammatory cascade, delaying immune...
- The National Institute of Allergy and Infectious Diseases awarded Albany Medical College $633,136 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate lung protective immunity elicited by a parental Yersinia-vesicle vaccine against pneumonic plague. The award funds research to decipher immune mechanisms in the lung following immunization with the MV46-LCRV vaccine candidate and upon pulmonary Yersinia pestis challenge. The project examines how...
- The National Institute of Allergy and Infectious Diseases awarded East Carolina University $536,695 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on May 1, 2026. The award funds research into the roles of fibroblastic reticular cells (FRCs) in the establishment and maintenance of HIV-1 latently infected cells containing intact proviruses in people living with HIV under antiretroviral therapy. The project examines how FRCs, a type of secondary lymphoid organ stromal...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $233,250 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate host-microbe interactions that drive pro-fibrotic macrophage phenotypes in inflammatory bowel disease. The research focuses on defining how adherent-invasive Escherichia coli (AIEC) and other intracellular bacteria manipulate human macrophage signaling and phenotype. The...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $427,625 on April 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into phage-mediated reprogramming of the gut microbiome to suppress chronic inflammation in inflammatory bowel disease. The funded research, R21AI197116, engineers self-complementary non-replicative phage vectors to deliver therapeutic genetic modifications to existing...
- The National Institute of Allergy and Infectious Diseases awarded the University of Arkansas for Medical Sciences $447,720 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and employ innovative in vitro and in vivo platforms for studying Acinetobacter baumannii ventilator-associated pneumonia (VAP) pathogenesis and prevention strategies. The research addresses a critical gap in VAP science: A. baumannii causes approximately 30 percent of...
- The National Institute of Allergy and Infectious Diseases awarded New York University $508,500 on April 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research investigating how myeloid cells, particularly neutrophils, regulate plasma membrane homeostasis to control decisions between functional immune programs including migration, phagocytosis, and netosis. The research, conducted as a postdoctoral project at New York University School of Medicine...